See more : China General Education Group Limited (2175.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Lavipharm S.A. (LAVI.AT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lavipharm S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Chimera Investment Corporation (CIM-PB) Income Statement Analysis – Financial Results
- Rémy Cointreau SA (RCO.PA) Income Statement Analysis – Financial Results
- SNT Holdings Co., Ltd. (036530.KS) Income Statement Analysis – Financial Results
- Wantedly, Inc. (3991.T) Income Statement Analysis – Financial Results
- Vontobel Holding AG (0QKE.L) Income Statement Analysis – Financial Results
Lavipharm S.A. (LAVI.AT)
About Lavipharm S.A.
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, general medicine, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products. The company was founded in 1911 and is based in Paiania, Greece.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.93M | 39.06M | 39.72M | 37.64M | 33.59M | 31.79M | 31.59M | 32.03M |
| Cost of Revenue | 27.73M | 22.68M | 25.03M | 22.54M | 18.64M | 17.05M | 17.35M | 17.48M |
| Gross Profit | 23.20M | 16.38M | 14.69M | 15.10M | 14.95M | 14.75M | 14.25M | 14.56M |
| Gross Profit Ratio | 45.54% | 41.93% | 36.99% | 40.12% | 44.50% | 46.38% | 45.09% | 45.44% |
| Research & Development | 195.00K | 365.00K | 342.00K | 302.00K | 290.00K | 410.00K | 299.00K | 249.00K |
| General & Administrative | 2.62M | 2.33M | 2.49M | 2.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.73M | 12.23M | 11.71M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.35M | 14.56M | 14.20M | 12.27M | 13.31M | 14.29M | 12.68M | 14.69M |
| Other Expenses | 413.00K | 1.24M | -548.00K | -573.00K | -469.00K | -420.00K | -73.00K | -2.24M |
| Operating Expenses | 23.20M | 13.69M | 15.09M | 13.14M | 14.07M | 15.12M | 13.06M | 17.18M |
| Cost & Expenses | 46.93M | 36.37M | 40.12M | 35.68M | 32.71M | 32.16M | 31.36M | 34.66M |
| Interest Income | 270.00K | 30.00K | 21.00K | 26.00K | 21.00K | 29.00K | 287.00K | 28.00K |
| Interest Expense | 2.27M | 1.64M | 1.83M | 1.92M | 1.93M | 1.93M | 1.99M | 4.60M |
| Depreciation & Amortization | 4.35M | 1.71M | 1.65M | 1.57M | 1.42M | 1.18M | 2.21M | 3.45M |
| EBITDA | 9.87M | 5.60M | 6.23M | 6.80M | 5.46M | 3.77M | 17.10M | 19.73M |
| EBITDA Ratio | 19.37% | 11.25% | 3.15% | 9.37% | 6.84% | 2.56% | 10.77% | 2.56% |
| Operating Income | 4.00M | 2.69M | -398.00K | 1.96M | 876.00K | -370.00K | 1.19M | -2.63M |
| Operating Income Ratio | 7.84% | 6.89% | -1.00% | 5.20% | 2.61% | -1.16% | 3.76% | -8.20% |
| Total Other Income/Expenses | -748.00K | -1.59M | -1.81M | -1.89M | -1.91M | 3.23M | 11.70M | 14.31M |
| Income Before Tax | 3.25M | 2.26M | 2.75M | 3.31M | 2.12M | 2.86M | 12.89M | 11.68M |
| Income Before Tax Ratio | 6.38% | 5.78% | 6.92% | 8.79% | 6.30% | 9.00% | 40.81% | 36.46% |
| Income Tax Expense | 1.25M | 1.31M | 1.02M | 1.21M | -3.21M | 1.61M | -37.00K | 2.81M |
| Net Income | 1.87M | 834.00K | 1.72M | 2.09M | 5.33M | 1.25M | 12.93M | 3.66M |
| Net Income Ratio | 3.67% | 2.14% | 4.34% | 5.56% | 15.86% | 3.93% | 40.91% | 11.43% |
| EPS | 0.01 | 0.04 | 0.09 | 0.11 | 0.29 | 0.07 | 0.71 | 0.20 |
| EPS Diluted | 0.01 | 0.04 | 0.09 | 0.11 | 0.29 | 0.07 | 0.71 | 0.20 |
| Weighted Avg Shares Out | 167.87M | 21.53M | 18.29M | 18.29M | 18.29M | 18.29M | 18.29M | 18.29M |
| Weighted Avg Shares Out (Dil) | 168.21M | 21.53M | 18.29M | 18.29M | 18.29M | 18.29M | 18.29M | 18.29M |
Source: https://incomestatements.info
Category: Stock Reports